Form 4: Vertex Pharmaceuticals Director Acquires Deferred Stock Units

Vertex Pharmaceuticals Director Suketu Upadhyay acquired 75.904 deferred stock units, increasing his beneficial ownership to 2,551.507 units.

Summary

• Suketu Upadhyay, a Director of Vertex Pharmaceuticals Inc. (VRTX), acquired 75.904 Deferred Stock Units (DSUs).
• The transaction date for this acquisition was July 15, 2025.
• Each DSU represents one share of Vertex Pharmaceuticals common stock and was valued at $469.34 per unit at the time of acquisition.
• Following this transaction, Mr. Upadhyay beneficially owns a total of 2,551.507 Deferred Stock Units.
• These DSUs are structured to be paid out in common stock upon the earliest occurrence of Mr. Upadhyay's termination of service on the board, a change of control of the company, or his disability or death.

Sentiment

Score: 7

Explanation: The acquisition of deferred stock units by a director is generally a positive signal as it aligns management's interests with shareholders, indicating confidence in the company's long-term prospects. It is a routine compensation event, so not highly impactful on its own, but contributes positively to governance alignment.

Positives

• Director Suketu Upadhyay increased his beneficial ownership in Vertex Pharmaceuticals through the acquisition of additional deferred stock units, which aligns his long-term interests with those of the company's shareholders.

Risks

• The ultimate value of the deferred stock units is directly dependent on the future performance and market price of Vertex Pharmaceuticals common stock until their conversion.

Future Outlook

The deferred stock units are structured to convert into common stock upon specific future events, including termination of service, a change of control, or the director's disability or death, aligning future compensation with long-term company performance.

Industry Context

This transaction represents a routine disclosure of director equity compensation, a common practice across the pharmaceutical and biotechnology industries, designed to align executive and director incentives with long-term shareholder value.

Comparison to Industry Standards

• The grant of deferred stock units is a standard form of equity compensation for directors in publicly traded companies, particularly within the biopharmaceutical sector, aiming to foster long-term commitment and align interests with shareholders.
• While specific comparable companies or projects are not detailed in this filing, such compensation structures are widely adopted by industry peers like Pfizer, Johnson & Johnson, and Moderna to retain talent and incentivize performance.

Stakeholder Impact

• Shareholders: Increased alignment of director's interests with long-term shareholder value due to equity compensation.

Next Steps

• The deferred stock units will convert into common stock upon the earliest of Mr. Upadhyay's termination of service on the board, a change of control of the company, or his disability or death.

Key Dates

Recommendation

Keywords

Vertex Pharmaceuticals, VRTX, SEC Form 4, Deferred Stock Units, DSU, Insider Transaction, Director Compensation, Equity Compensation